Characteristics | Malignant lymphoma (n = 37) | Inflammatory lymphadenopathy (n = 22) | P |
---|---|---|---|
Sex, n (%) | |||
Male/female | 33 (89.2%)/4 (10.8%) | 19 (86.4%)/3 (13.6%) | 0.751 |
Median age (y) | 43 (26–75) | 42.5 (23–74) | 0.714 |
Presenting syndrome, n (%) | |||
Fever (> 38℃) | 12 (32.4%) | 12 (54.5%) | 0.109 |
Fatigue | 6 (16.2%) | 8 (36.4%) | 0.114 |
Cough | 5 (13.5%) | 9 (40.9%) | 0.055 |
Weight loss | 14 (37.8%) | 10 (45.5%) | 0.789 |
Nausea and vomiting | 3 (8.1%) | 2 (9.1%) | 1.000 |
Night sweats | 3 (8.1%) | 2 (9.1%) | 1.000 |
Local pain | 15 (40.5%) | 6 (27.3%) | 0.402 |
KPS, median (interquartile range) | 80 (40–90) | 90 (70–90) | 0.015* |
ECOG, n (%) | 0.013* | ||
0/1 | 23 (62.2%) | 19 (86.4%) | 0.074 |
2/3 | 14 (37.8%) | 3 (13.6%) | 0.074 |
4/5 | 0 (0%) | 0 (0%) | NA |
Duration of HIV infection (months), median (interquartile range) | 3 (0–96) | 7 (0–108) | 0.303 |
Duration of anti-HIV therapy (months), median (interquartile range) | 2(0–96) | 6 (0–108) | 0.193 |
WHO clinical stage of HIV on admission, n (%) | 0.844 | ||
I | 16 (43.2%) | 8 (36.4%) | 0.785 |
II | 3 (8.1%) | 3 (13.6%) | 0.666 |
III | 9 (24.3%) | 6 (13.6%) | 1.000 |
IV | 9(24.3%) | 5 (22.7%) | 0.748 |
Laboratory examination, median (interquartile range) | |||
White cell count (10E9/L) | 4.6 (0.5–35.9) | 3.5 (1.9–8.6) | 0.218 |
N (10E9/L) | 2.4 (0.30–7.7) | 1.8 (1.1–6.9) | 0.707 |
L (10E9/L) | 1.1 (0.1–2.4) | 0.7 (0.2–1.8) | 0.014* |
Platelet count (10E9/L) | 148.0 (14.0–429.0) | 3.2 (2.2–5.0) | 0.563 |
Red-cell count(10E9/L) | 3.70 (2.06–5.43) | 198.0 (36.0–414.0) | 0.121 |
Hematocrit (%) | 33.9 (18.5–44.9) | 31.3 (21.9–44.5) | 0.462 |
Hemoglobin (g/dL) | 116.0 (63.0–158.0) | 110.1 (65.0–152.0) | 0.533 |
C-reactive protein (mg/L) | 18.3 (0–218.8) | 28.2 (0.6–125.2) | 0.304 |
Erythrocyte sedimentation rate (mm/H) | 21.0 (2.0–105.0) | 29.0 (3.0–117.0) | 0.779 |
Lactate dehydrogenase (U/L) | 465 (134–8396) | 218 (139–876) | 0.010* |
Ferritin (ng/mL) | 398.8 (7.4–40,000.0) | 534.9 (66.8–3524.0) | 0.385 |
CD4 (cells/μL) | 128 (4–714) | 137 (10–399) | 0.910 |
CD4/CD8 | 0.25 (0.01–0.87) | 0.28 (0.02–1.47) | 0.255 |
T-spot (+), n (%) | 3 (8.1%) | 8 (36.4%) | 0.013* |
EBV (+), n (%) | 22 (59.4%) | 9 (40.9%) | 0.189 |
Numbers of lymph node involved areas median (interquartile range) | 6 (1–11) | 3 (1–9) | 0.006* |
Maximum diameter of lymph nodes (cm), median (interquartile range) | 4.0 (1.0–19.1) | 1.8 (1.1–5.8) | 0.001* |
Morphological features of lymph nodes, n% | |||
Fusion | 17 (45.9%) | 3 (13.6%) | 0.021 |
Necrosis | 4 (10.8%) | 6 (27.3%) | 0.152 |
Calcification | 0 (0%) | 2 (9.1%) | 0.135 |
FDG accumulation in extra-lymphatic organs, n% | 31 (83.8%) | 12 (54.5%) | 0.000* |
Bone marrow | 16 (43.2%) | 4 (18.2%) | 0.098 |
Spleen | 10 (27.0%) | 9 (9.1%) | 0.388 |
Digestive tract | 11 (29.7%) | 0 (0%) | 0.004* |
Waldeyer’s ring | 13 (35.1%) | 2 (9.1%) | 0.033* |
Liver | 11 (29.7%) | 1 (4.5%) | 0.053 |
Nasal and sinuses | 3 (8.1%) | 0 (0%) | 1.000 |
Pancreas | 3 (8.1%) | 1 (4.5%) | 1.000 |
Adrenal | 3 (8.1%) | 0 (0%) | 0.286 |
Skin | 2 (5.4%) | 0 (0%) | 0.524 |
Peritoneum | 2 (5.4%) | 0 (0%) | 0.524 |
CNS | 1 (2.7%) | 0 (0%) | 1.000 |
SUV measurement, median (interquartile range) | |||
SUVLN | 18.5 (3.6–32.0) | 5.2 (1.3–22.6) | 0.000* |
SUVMarrow | 3.1 (1.3–21.8) | 3.2 (1.6–8.2) | 0.002* |
SUVSpleen | 2.4 (1.3–12.2) | 2.4 (1.6–7.9) | 0.700 |
SUVLiver | 2.7 (1.3–16.3) | 2.6 (1.7–4.7) | 0.017* |
SURmax | 7.9 (2.1–15.5) | 3.0 (0.6–8.4) | 0.000* |